New Rheumatoid Arthritis Test May Improve Drug Response
A new blood test could help adults with rheumatoid arthritis identify if they are likely to respond to the drug abatacept.
Updated on Oct. 28, 2026 in Arthritis
Live Poll
Do you believe personalized genetic testing helps patients find the most effective medical treatments?
Scipher Medicine announced an early access program for its new blood-based test, PrismTcell, designed to predict how patients with rheumatoid arthritis will respond to the medication abatacept. The program is expected to launch in early 2027 to help doctors select more effective treatment paths for their patients.
Why it matters
Identifying effective treatments for rheumatoid arthritis often involves trial and error, which can delay symptom relief and disease management. This test aims to help physicians predict a patient's response to abatacept before treatment begins, potentially improving clinical outcomes.
Data from the two-year PREDICT study, involving over 40 clinical sites, showed that using the PrismTcell molecular signature resulted in an approximately 2-fold higher ACR50 response rate compared to standard care. These preliminary findings validate the test's ability to predict response to abatacept.
The players
Scipher Medicine
A biotechnology company focused on developing precision diagnostics and therapeutics for immune-mediated diseases.
The details
The test functions by analyzing a patient's molecular signatures, including transcriptomic profiles and SNP genotyping, from a standard blood sample. By identifying these biological markers, the test indicates which patients are more likely to respond positively to abatacept. The testing is performed in a CLIA-certified and CAP-accredited laboratory to ensure standardized clinical results for practitioners.
Timeline
October 28, 2026: The company announced the upcoming early access program.
November 10, 2026: Clinical data is scheduled for presentation at ACR Convergence 2026.
Early Q1 2027: The expected launch date for the PrismTcell Early Access Program.
Health Landscape
This development marks a significant move toward precision medicine within the rheumatology sector, aiming to replace generalized treatment protocols with biology-informed decisions. It aligns with broader industry trends at ACR Convergence that prioritize molecular profiling to improve drug efficacy.
If you are currently managing rheumatoid arthritis, it is worth discussing with your rheumatologist whether molecular diagnostic testing could help tailor your treatment plan in the future. This test is intended to inform physician decision-making regarding the use of abatacept.
The takeaway
Predictive testing aims to simplify the complex process of selecting effective rheumatoid arthritis therapies by leveraging biological signatures. Patients should monitor their disease activity markers and consult their physician about new diagnostic options that may become available in the coming year.
What happens next
The clinical validation data for the test will be presented during the ACR Convergence 2026 conference on November 10, 2026.
Further reading
Learn more about the latest innovations in managing Arthritis care.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe personalized genetic testing helps patients find the most effective medical treatments?
